1. Home
  2. NRSN vs MBRX Comparison

NRSN vs MBRX Comparison

Compare NRSN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$1.25

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

SELL

Current Price

$7.60

Market Cap

6.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NRSN
MBRX
Founded
2017
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
6.4M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
NRSN
MBRX
Price
$1.25
$7.60
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$91.75
★ $240.00
AVG Volume (30 Days)
★ 40.8K
35.7K
Earning Date
09-25-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.16
52 Week High
$7.50
$10.24

Technical Indicators

Market Signals
Indicator
NRSN
MBRX
Relative Strength Index (RSI) 31.98 59.55
Support Level $0.70 $2.12
Resistance Level $2.17 $10.24
Average True Range (ATR) 0.24 0.73
MACD 0.02 -0.36
Stochastic Oscillator 8.25 41.57

Price Performance

Historical Comparison
NRSN
MBRX

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: